[ad_1]
Zurich (awp) – Cosmo regains new success with its active ingredient rifamycin SV MMX: the licensee Dr. Falk has obtained the approval of Relafalk, a drug based on this active ingredient, to treat the tourist's diarrhea as part of of a decentralized procedure in Europe, said Cosmo Wednesday evening.
Approval applies to Germany, Great Britain, Spain, Denmark, Greece, Finland, Hungary, Norway, Portugal, Poland, Sweden and Bulgaria.
Relafalk is an oral antibiotic. Just two weeks ago, the US FDA approved the product.
rw / rp
Source link
